HER2 Receptor Antagonist

DrugDrug NameDrug Indication
DB00072TrastuzumabIndicated for treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
DB06366PertuzumabPertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.